1. Holloway K, Green T, Carandang E, Hogerzeil H, Laing R, Lee D. Drug and therapeutics committees A
practical guide. World Health Organization. https://apps.who.int/medicinedocs/en/d/Js4882e/ (2003).
2. Bamigboye BT, Olowe OA, Taiwo SS. Phenotypic and molecular identification of vancomycin resistance in
clinical Staphylococcus aureus isolates in Osogbo, Nigeria. Eur J Microbiol Immunol 2018; 8: 25-30
3. Périchon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents
Chemother. 2009; 53: 4580-7.
4. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and
development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet
Infect Dis. 2018; 18: 318-27.
5. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe –
Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. Stockholm:
ECDC; 2018.
6. Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare
Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of
Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis
1997; 25: 584-99
7. Navarro R. Drug Utilization Review Strategies. In Managed Care Pharmacy Practice 2008, 215-229.
8. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin
therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of
america, the american society of health-system pharmacists, and the society of infectious diseases pharmacists.
Clin Infect Dis 2009; 49: 325-7
9. Pharmaceutical Trends Overview Report. http://www.pmprb-cepmb.gc.ca/CMFiles/PTOR_June_0638MBI6232006-5829.pdf. 2006
10. Mousavi S, Behi M, Taghavi MR, Ahmadvand A, Ziaie S, Moradib M. Drug utilization evaluation of
imipenem and intravenous ciprofloxacin in a teaching hospital. Iran J Pharm Res 2013; 12: 161-7.
11. Nateghian AR, Robinson JL, Samadi B, Abdi N. Appropriate use of vancomycin in an educational tertiary care
hospital in Tehran, Iran. Med J Islam Repub Iran 2007; 21: 43-9.
12. Floret N, Thouverez M, Talon D, Thalamy B, Estavoyer JM. Evaluation of vancomycin use in a large
university‐ affiliated hospital in eastern France in 1999. Pharm World Sci 2001; 23: 93-7.
13. Vazin A, Japoni A, Shahbazi S, Davarpanah MA. Vancomycin utilization evaluation at hematology-oncology
ward of a teaching hospital in Iran. Iran J Pharm Res 2012; 11: 163-70
14. Raveh D, Muallem-zilcha E, Greenberg A, Wiener-well Y, Schlesinger Y, Yinnon AM. Prospective drug
utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and
meropenem. Q J Med 2006; 99: 397-406.
15. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, et al. Meropenem and
piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect
pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 2013; 17:
R84.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In:
CLSI document M100S, 26th edn, Wayne: Clinical and Laboratory Standards Institute. 2016
)